Search Within

Gynecology Disease Management Team

Formats
  1. Journal Article (2473)
  2. Meeting Abstract (2112)
  3. Book Section (226)
  4. Review (135)
  5. Editorial (88)
  6. Guidelines (39)
  7. Correspondence (19)
  8. Conference Paper (16)
  9. Miscellaneous (13)
  10. Research Letter (12)
  11. Book Whole (11)
Groups
  1. Surgery (2362)
  2. Department of Medicine (2268)
  3. Solid Tumor Oncology Division (2217)
  4. GDMT, Surgery (1974)
  5. GDMT, Medicine (1910)
  6. Gynecologic Medicine Service (1877)

More Groups

People
  1. Nadeem Abu-Rustum (902)
  2. Robert Soslow (797)
  3. Dennis Chi (716)
  4. Britta Weigelt (646)
  5. Carol Aghajanian (615)
  6. Mario Leitao (582)

More People

Years
  1. 2025 (161)
  2. 2024 (308)
  3. 2023 (332)
  4. 2022 (361)
  5. 2021 (308)
  6. 2020 (356)

More Years

Publications
  1. Gynecologic Oncology (950)
  2. Journal of Clinical Oncology (543)
  3. Modern Pathology (354)
  4. International Journal of Gynecological Cancer (321)
  5. Laboratory Investigation (311)
  6. International Journal of Radiation Oncology, Biology, Physics (223)

More Publications

Publishers
  1. Elsevier B.V. (1001)
  2. American Society of Clinical Oncology (598)
  3. Lippincott Williams & Wilkins (584)
  4. Elsevier Inc. (481)
  5. Nature Publishing Group (424)
  6. Nature Research (356)

More Publishers

Results (5144)


Citation style sort is year ascending, and then by author or title. Author ascending is default.
  • Clinical activity of tazemetostat, an EZH2 inhibitor, among patients with advanced endometrioid endometrial cancer and ovarian clear cell carcinoma with and without ARID1A mutations (NRG-GY014)
    Meeting Abstract

    Schram, A.; Eskander, R.; Sill, M.; Hagemann, A.; Waggoner, S.; Press, J.; Ghamande, S.; Zivanovic, O.; Bottsford-Miller, J.; Aghajanian, C.
    Gynecologic Oncology (2024)

    Fulltext@MSK | Save
  • Overall survival and progression-free survival by PD-L1 status among endometrial cancer patients treated with pembrolizumab plus carboplatin/paclitaxel as compared to carboplatin/paclitaxel plus placebo in the NRG GY018 trial
    Meeting Abstract

    Eskander, R.; Sill, M.; Beffa, L.; Moore, R.; Hope, J.; Musa, F.; Mannel, R.; Shahin, M.; Cantuaria, G.; Girda, E.; more...
    Gynecologic Oncology (2024)

    Fulltext@MSK | Save
  • Efficacy and safety of trastuzumab deruxtecan among patients with HER2-expressing solid tumors: Biomarker and subgroup analyses from the cervical, endometrial, and ovarian cancer cohorts of the DESTINY-PanTumor02 study
    Meeting Abstract

    Makker, V.; Oaknin, A.; Manso, L.; González-Martín, A.; Lugowska, I.; Meric-Bernstam, F.; Lorusso, D.; Banerjee, S.; Liao, J.; Siena, S.; more...
    Gynecologic Oncology (2024)

    Fulltext@MSK | Save
  • Efficacy and safety of alpelisib plus olaparib versus chemotherapy among patients with platinum-resistant or refractory high-grade serous ovarian cancer without BRCA mutation: Primary analysis of the EPIK-O trial
    Meeting Abstract

    Konstantinopoulos, P.; Kim, J. W.; Freyer, G.; Lee, J. Y.; Gaba, L.; Grisham, R.; Colombo, N.; Wu, X.; Sehouli, J.; Cruz, F.; more...
    Gynecologic Oncology (2024)

    Fulltext@MSK | Save
  • Successful implementation of a goals-to-discharge patient checklist following surgery for gynecologic cancer
    Meeting Abstract

    Byrne, M.; Roche, K. L.; Chi, D.; Sonoda, Y.; Abu-Rustum, N.; Gardner, G.; Broach, V.
    Gynecologic Oncology (2024)

    Fulltext@MSK | Save
  • Sexual function and menopausal symptoms among patients at high risk of ovarian carcinoma undergoing interval salpingectomy or risk-reducing salpingo-oophorectomy in the prospective multicenter WISP trial
    Meeting Abstract

    Norquist, B.; Nebgen, D.; Roche, K. L.; Bakkum-Gamez, J.; Romero, I.; Feltmate, C.; Levine, D.; Kim, S.; Hagemann, A.; Carter, J.; more...
    Gynecologic Oncology (2024)

    Fulltext@MSK | Save
  • First clinical results from a phase 1 trial of PRT3789, a first-in-class intravenous SMARCA2 degrader, in patients with advanced solid tumors with a SMARCA4
    Meeting Abstract

    Yap, T. A.; Dowlati, A.; Dagogo-Jack, I.; Vibert, J.; Spira, A. I.; Moreno Garcia, V.; Punekar, S. R.; Calvo, E.; Sonpavde, G. P.; Awad, M.; more...
    European Journal of Cancer (2024)

    Fulltext@MSK | Save
  • Longer-term safety and efficacy of selinexor maintenance therapy for patients with TP53wt advanced or recurrent endometrial cancer: Follow-up subgroup analysis of the ENGOT-EN5/GOG-3055/SIENDO study
    Meeting Abstract

    Haluska, P.; Pérez-Fidalgo, J. A.; Vergote, I.; Hamilton, E.; de Giorgi, U.; Van Gorp, T.; Lübbe, K.; Zikan, M.; Helpman, L.; Miller, D. S.; more...
    Asia-Pacific Journal of Clinical Oncology (2024)

    Fulltext@MSK | Save
  • ENGOT-EN20/GOG-3083/XPORT-EC-042 A PHASE 3, randomized, placebo-controlled, double-blind, multicenter trial of Selinexor in maintenance therapy for patients with p53 wild-type, advanced or recurrent endometrial carcinoma
    Meeting Abstract

    Webber, K.; Vergote, I.; Mirza, M. R.; Coleman, R.; Fidalgo, J. A. P.; Monk, B. J.; Valabrega, G.; Slomovitz, B.; Van Gorp, T.; Moore, K.; more...
    Asia-Pacific Journal of Clinical Oncology (2024)

    Fulltext@MSK | Save
  • Clinical and biomarker data from a phase 1/2 trial of ifinatamab deruxtecan (I-DXd; DS-7300) in advanced solid tumors
    Meeting Abstract

    Doi, T.; Patel, M. R.; Koyama, T.; Falchook, G. S.; Friedman, C.; Piha-Paul, S. A.; Gutierrez, M.; Awad, M.; Mattour, A.; Satoh, T.; more...
    Annals of Oncology (2024)

    Fulltext@MSK | Save